Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px
Organisation › Details

Ipsen S.A. (Euronext: IPN; ADR: IPSEY)

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditure totaled close to €193 million. The Group has more than 4,600 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. *

 

Period Start 2007-08-25 existent
  Group Ipsen (Group)
Product Industry pharmaceutical
Person Person Meek, David (Ferring 202001– CEO of FerGene before Ipsen + Baxalta + Endocyte + Novartis + JnJ)
     
Region Region Paris
  Country France
  Street 42 rue du Docteur Blanche
  City 75016 Paris
  Tel +33-1-443043-43
    Address record changed: 2018-07-24
     
Basic data Employees F: 1,001 to 5,000 (2017-02-23)
  Currency EUR
  Annual sales 1,671,100,000 (revenue, consolidated (2016) 2016-12-31)
  Profit 226,600,000 (2016-12-31)
  Cash 425,500,000 (2016-12-31)
     
    * Document for �About Section�: Ipsen S.A.. (3/1/16). "Press Release: Ipsen’s 2015 Results and 2016 Financial Objectives". Paris.
     
   
Record changed: 2020-01-27

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 650x65px

More documents for Ipsen (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top